Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Anti-HIV Immune Serum Globulin (Human)
Anti-HIV Immune Serum Globulin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Anti-HIV Immune Serum Globulin (Human) | DRUG | - |
Inclusion Criteria Patients must have: * Proof of HIV infection. * Diagnosis of asymptomatic HIV infection or early AIDS related complex (ARC) with no zidovudine (AZT) or other anti-HIV therapy. OR a diagnosis of AIDS and = or \> 3 months of AZT therapy. Exclusion Criteria Co-existing Condition:...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Anti-HIV Immune Serum Globulin is an investigational therapy developed by Abbott Laboratories for HIV Infections. It is also known as Anti-HIV Immune Serum Globulin (Human). It has been studied in a Phase 1 clinical trial and is not approved for use.
Anti-HIV Immune Serum Globulin is being studied for the treatment of HIV Infections. It is an investigational product and has not been approved for any indication.
Anti-HIV Immune Serum Globulin is developed by Abbott Laboratories, which trades under the ticker symbol ABT.
Anti-HIV Immune Serum Globulin is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing.
Anti-HIV Immune Serum Globulin has been evaluated in a single Phase 1 trial, NCT00002036, titled "Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)." The trial enrolled 12 participants and has been completed.
Yes, Anti-HIV Immune Serum Globulin is also known as Anti-HIV Immune Serum Globulin (Human). Both names refer to the same investigational product developed by Abbott Laboratories.